
Reta GLP-3
Retatrutide research peptide, an investigational GIP, GLP-1 and glucagon receptor triple agonist. 99%+ HPLC, COA on request. Research use only. · USD
Product details
About Reta GLP-3
Retatrutide is a synthetic peptide that acts as an agonist at three receptors: GIP, GLP-1 and glucagon. It is a lipidated peptide developed by Eli Lilly under the code LY3437943.
Research background
Retatrutide is an investigational compound that has not been approved by the FDA or any other regulator. In the laboratory it is used to study multi-receptor signalling and receptor-selectivity in cell-based assays. This product is research material and is not manufactured for human use.
Specifications
- Form: lyophilised (freeze-dried) powder
- Purity: 99%+ by HPLC
- Documentation: Certificate of Analysis available on request
- Storage: keep the sealed vial cold and away from light and moisture
For laboratory research use only
This product is supplied strictly for in-vitro laboratory research by qualified professionals. It is not a drug, dietary supplement or cosmetic, has not been evaluated by the FDA, and is not for human or animal consumption or for any diagnostic or therapeutic use.
